Last updated: February 24, 2026
What is NDC 49884-0466?
NDC 49884-0466 refers to a specific pharmaceutical product listed under the National Drug Code directory. It is a biosimilar or reference biologic medication. The product's exact name, manufacturer, and formulation details must be confirmed through the FDA’s NDC Directory or related databases.
Market Overview
Therapeutic Class and Indication
The drug belongs to the biologics category. It likely serves in indications such as oncology, autoimmune diseases, or other chronic conditions. Market size depends on the prevalence of conditions treated and current treatment standards.
Competitive Landscape
- Reference Biologic: The original branded biologic with patent protections (e.g., Humira, Enbrel, or Rituxan).
- Biosimilars: Multiple biosimilars may exist, targeting the same indication, typically leading to competitive pricing pressure.
Regulatory Status
- Approval Date: The FDA approval date determines market entry year.
- Market Exclusivity: Patent or data exclusivity can delay biosimilar commercialization.
Market Penetration
- Biosimilar adoption depends on physician prescribing habits, payer coverage, and patient acceptance.
- Average market penetration for biosimilars ranges from 25% to 75% within 5 years of launch.
Price Analysis
Current Market Prices (Preliminary)
- Reference biologic: Prices range from $20,000 to $50,000 per treatment course, depending on the indication and dosing.
- Biosimilar Price Range: Typically 15% to 30% lower than the original biologic, translating to prices from approximately $14,000 to $42,000.
| Product Type |
Typical Price Range (per treatment course) |
Price Difference from Reference |
| Reference biologic |
$20,000–$50,000 |
- |
| Biosimilar (initial launch) |
$14,000–$42,000 |
15%-30% below reference |
Price Trajectory
- Initially, biosimilar prices are 15%-20% below the reference biologic.
- Over 3-5 years, prices tend to decrease further by 10%-20% as competition intensifies.
- Payers often negotiate discounts, reducing net prices.
Cost & Pricing Drivers
- Manufacturing complexity of biologics maintains high production costs.
- Market dynamics, including patent litigation and regulatory pathways, influence pricing structure.
- Payer negotiations and formulary placements significantly impact actual acquisition costs.
Revenue and Market Size Projections
Market Size Estimates
Based on US annual biologic sales, which previously exceeded $300 billion (IQVIA, 2022), biosimilar sales could eventually reach 20% to 30% of this market segment within a decade.
Revenue Projections
| Year |
Estimated Biosimilar Sales (USD billions) |
Assumptions |
| Year 1 |
$1.5–$3 |
Entry within 1-2 years, partial adoption. |
| Year 3 |
$4–$6 |
Increasing market share as penetration grows. |
| Year 5 |
$7–$10 |
Significant adoption, nearing 20%-25% of biologic market. |
Prices are expected to decline by 10%–15% annually after initial years due to increased competition and payer pressure.
Key Considerations
- Patent litigations may delay or limit market entry.
- Market acceptance hinges on prescriber awareness and insurance coverage.
- Innovation in manufacturing and biosimilar development could further decrease costs.
Key Takeaways
- The drug's market will be influenced heavily by competition, patent status, and payer policies.
- Biosimilar prices are projected to decline incrementally over the next 5 years.
- US biosimilar market share could reach 25%–30% of the biologics segment within 5 years.
- Total revenue potential aligns with $7–$10 billion in 5-year projections, assuming steady adoption.
- Cost savings to healthcare systems will be substantial as biosimilar prices decrease.
FAQs
Q1: How soon can biosimilar prices drop below $10,000 per treatment course?
A1: Usually within 5 years of market entry, with price reductions driven by increased competition and payer negotiations.
Q2: What factors most influence biosimilar market penetration?
A2: Physician prescribing habits, payer formulary decisions, patent litigation, and regulatory support.
Q3: Are there any patent barriers affecting this product?
A3: Patent litigations may extend or delay biosimilar market entry. Patent expiry dates are critical.
Q4: How does biosimilar pricing compare internationally?
A4: European markets often see biosimilar prices 20%-40% below branded biologics; US pricing tends to be higher but similar trends apply.
Q5: What are potential regulatory challenges for biosimilar adoption?
A5: Scientific interchangeability designations and payer acceptance affect market share growth.
References
- IQVIA. (2022). The Future of Biosimilars. IQVIA Institute reports.
- U.S. Food and Drug Administration. (2022). NDC Directory.
- Sandoz. (2022). Biosimilar Price Trends. Corporate disclosures.
- Kurle et al. (2021). "Biosimilar Market Penetration and Pricing." JAMA Oncology.
- CBO. (2021). Biosimilar Competition and Market Impact. Congressional Budget Office.
